13/04/2022.
Melanoma has a poor prognosis with median survival of 6-9 months in the absence of timely diagnosis and treatment.
Thanks to the introduction of novel, highly effective but also costly therapies (immune therapies with anti-PD1 and anti-CTL4, and targeted therapies for BRAF mutant melanoma), overall survival has now considerably increased to over 50% at five years.
Keep reading at The importance of Early Detection in the light of COVID-19.